Dual versus single energy cardiac CT to measure extracellular volume in cardiac amyloidosis: correlations with cardiac MRI

Scully, 2018, Myocardial Extracellular Volume Quantification by Cardiovascular Magnetic Resonance and Computed Tomography, Curr. Cardiol. Rep., 20, 15, 10.1007/s11886-018-0961-3 Frangogiannis, 2017, The extracellular matrix in myocardial injury, repair, and remodeling, J. Clin. Invest., 127, 1600, 10.1172/JCI87491 Small, 2021, Cardiac Computed Tomography for Amyloidosis, Curr. Cardiovasc. Imaging Reports, 14, 10, 10.1007/s12410-021-09560-8 Fontana, 2015, Cardiovascular magnetic resonance for amyloidosis, Heart Fail. Rev., 20, 133, 10.1007/s10741-014-9470-7 Bandula, 2013, Measurement of myocardial extracellular volume fraction by using equilibrium contrast-enhanced CT: validation against histologic findings, Radiology, 269, 396, 10.1148/radiol.13130130 Treibel, 2015, Extracellular volume quantification by dynamic equilibrium cardiac computed tomography in cardiac amyloidosis, J. Cardiovasc. Comput. Tomogr., 9, 585, 10.1016/j.jcct.2015.07.001 Dang, 2020, Gateway and journey of patients with cardiac amyloidosis, ESC Heart Fail., 7, 2418, 10.1002/ehf2.12793 Scully, 2020, Identifying Cardiac Amyloid in Aortic Stenosis: ECV Quantification by CT in TAVR Patients, JACC Cardiovasc. Imaging, 10.1016/j.jcmg.2020.05.029 Wang, 2018, Extracellular volume quantitation using dual-energy CT in patients with heart failure: Comparison with 3T cardiac MR, Int. J. Cardiol., 268, 236, 10.1016/j.ijcard.2018.05.027 Suzuki, 2021, Prognostic Impact of Myocardial Extracellular Volume Fraction Assessment Using Dual-Energy Computed Tomography in Patients Treated With Aortic Valve Replacement for Severe Aortic Stenosis, J. Am. Heart Assoc., 10.1161/JAHA.120.020655 van Assen, 2019, Feasibility of extracellular volume quantification using dual-energy CT, J. Cardiovasc. Comput. Tomogr., 13, 81, 10.1016/j.jcct.2018.10.011 Gama, 2022, Extracellular Volume Fraction by Computed Tomography Predicts Long-Term Prognosis Among Patients With Cardiac Amyloidosis, JACC Cardiovasc. Imaging, 10.1016/j.jcmg.2022.08.006 Gillmore, 2016, Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis, Circulation, 133, 2404, 10.1161/CIRCULATIONAHA.116.021612 Kramer, 2020, Standardized cardiovascular magnetic resonance imaging (CMR) protocols: 2020 update, J. Cardiovasc. Magn. Reson., 22, 17, 10.1186/s12968-020-00607-1 Walpot, 2019, Left Ventricular Mid-Diastolic Wall Thickness: Normal Values for Coronary CT Angiography, Radiol. Cardiothorac. Imaging, 1, e190034, 10.1148/ryct.2019190034 Small, 2011, Established and emerging dose reduction methods in cardiac computed tomography, J. Nucl. Cardiol., 18, 570, 10.1007/s12350-011-9400-1 Emoto, 2021, Myocardial Extracellular Volume Quantification Using Cardiac Computed Tomography: A Comparison of the Dual-energy Iodine Method and the Standard Subtraction Method, Acad. Radiol., 28, 10.1016/j.acra.2020.03.019 Qi, 2021, Myocardial extracellular volume fraction quantitation using cardiac dual-energy CT with late iodine enhancement in patients with heart failure without coronary artery disease: A single-center prospective study, Eur. J. Radiol., 140, 10.1016/j.ejrad.2021.109743 Scully, 2020, DPD Quantification in Cardiac Amyloidosis: A Novel Imaging Biomarker, JACC Cardiovasc. Imaging, 13, 1353, 10.1016/j.jcmg.2020.03.020 Fontana, 2021, Reduction in CMR Derived Extracellular Volume With Patisiran Indicates Cardiac Amyloid Regression, JACC Cardiovasc. Imaging, 14, 189, 10.1016/j.jcmg.2020.07.043